PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-21.98%
Both yoy net incomes decline, with AVXL at -18.49%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
22.78%
D&A growth of 22.78% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
128.24%
SBC growth while AVXL is negative at -10.16%. John Neff would see competitor possibly controlling share issuance more tightly.
-92.68%
Negative yoy working capital usage while AVXL is 136.40%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
314.60%
AP growth well above AVXL's 124.71%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
26.98%
Lower 'other working capital' growth vs. AVXL's 150.68%. David Dodd would see fewer unexpected short-term demands on cash.
-101.99%
Both negative yoy, with AVXL at -52.46%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-120.47%
Negative yoy CFO while AVXL is 26.83%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
72.96%
CapEx growth of 72.96% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
72.96%
We expand invests by 72.96% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
86.96%
Debt repayment growth of 86.96% while AVXL is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-90.54%
Both yoy lines negative, with AVXL at -45.54%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.